Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial.

Background: Frailty may modify the risk-benefit profile of certain treatments, and frail patients may have reduced tolerance to treatments.Objective: To investigate the efficacy of dapagliflozin according to frailty status, using the Rockwood cumulative deficit approach, in DAPA-HF (Dapagliflozin an...

Descripción completa

Detalles Bibliográficos

Publicado en:	Annals of Internal Medicine Vol. 175; no. 6; pp. 820 - 831
Autores principales:	Butt, Jawad H, Dewan, Pooja, Merkely, Béla, Belohlávek, Jan, Drożdż, Jarosław, Kitakaze, Masafumi, Inzucchi, Silvio E, Kosiborod, Mikhail N, Martinez, Felipe A, Tereshchenko, Sergey, Ponikowski, Piotr, Bengtsson, Olof, Lindholm, Daniel, Langkilde, Anna Maria, Schou, Morten, Sjöstrand, Mikaela, Solomon, Scott D, Sabatine, Marc S, Chiang, Chern-En, Docherty, Kieran F
Formato:	clinical trial research randomized controlled trial Journal Article
Publicado:	American College of Physicians Jun2022
Acceso en línea:	Ver este registro en EBSCOhost